摘要
背景:在进化上保守的Hedgehog(HH)信号通路之一是许多后生动物胚胎发育的关键因子。这条途径被小摩尔广泛地瞄准。分子抑制剂为失调导致各种恶性肿瘤和发育障碍。因此,阻断这种通路可能是治疗刺猬依赖C的一种新的治疗途径。ancers。本文综述了Hedgehog信号在脊椎动物细胞中的作用机制,概述了小分子HH通路抑制剂的合成路线和研究进展。其中一些简要讨论。 方法:综合报道了与合成和自然发生的HH信号拮抗剂有关的文献。 结果:由于靶向小分子的选择性,这一肿瘤治疗途径与激酶、微管蛋白或HDAC抑制剂相比,已经发现了一些这样的拮抗剂,其中S有些人是在临床前开发和临床研究。大多数报道的小分子拮抗剂主要是平滑的受体虽然靶向GLI1转录因子和嘘我-配体也被发现。到目前为止,九个SMO拮抗剂已在临床trials.gdc -评价0449 / vismodegib和nvp-lde225 / erismodegib,被授予由美国食品和药物管理局(FDA)批准了基底细胞癌的治疗。
关键词: Hedgehog通路,小分子,平滑,GLI,抑制剂,抗癌。
Current Medicinal Chemistry
Title:Discovery of Hedgehog Antagonists for Cancer Therapy
Volume: 24 Issue: 19
关键词: Hedgehog通路,小分子,平滑,GLI,抑制剂,抗癌。
摘要: Background: The evolutionarily conserved Hedgehog (Hh) signaling cascade is one of the key mediators of embryonic development of many metazoans. This pathway has been extensively targeted by small molecule inhibitors as its misregulation leads to various malignancies and developmental disorders. Thus, blocking this pathway can be a novel therapeutic avenue for the treatment of Hedgehog-dependent cancers. This review covers the mechanism of hedgehog signaling in vertebrate cells, provides an overview of reported small molecule Hh pathway inhibitors, with the synthetic routes and SAR studies of some of them discussed briefly.
Methods: A comprehensive survey of literature related to synthetic and naturally occurring Hh signaling antagonists reported till date is presented. Results: Given the selectivity of small molecules targeting, this pathway for cancer treatment compared to kinase, tubulin or HDAC inhibitors, several such antagonists have been discovered, of which some are in preclinical development and clinical studies. Most of the reported small molecules primarily antagonize the Smoothened receptor although agents targeting Gli1 transcription factor and Shh ligand have also been discovered. Till date, nine Smo antagonists have been evaluated in clinical trials.GDC- 0449/Vismodegib and NVP-LDE225/Erismodegib, were granted approval by the U.S. Food and Drug Administration (U.S. FDA) for the treatment of basal cell carcinoma. Conclusion: The challenge is to identify agents that target the pathway downstream of Smo and develop strategies to overcome acquired drug resistance to the current Smo inhibitors with deeper understanding of the resistance mechanisms.Export Options
About this article
Cite this article as:
Discovery of Hedgehog Antagonists for Cancer Therapy, Current Medicinal Chemistry 2017; 24 (19) . https://dx.doi.org/10.2174/0929867324666170316115500
DOI https://dx.doi.org/10.2174/0929867324666170316115500 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Gadd45 Proteins as Critical Signal Transducers Linking NF-κB to MAPK Cascades
Current Cancer Drug Targets Human UDP-Glucuronosyltransferase 2B7
Current Drug Metabolism Dipyridamole: A Drug with Unrecognized Antioxidant Activity
Current Topics in Medicinal Chemistry Hutchinson-Gilford Progeria Syndrome (Hgps) and Application of Gene Therapy Based Crispr/Cas Technology as A Promising Innovative Treatment Approach
Recent Patents on Biotechnology Role of Serum and Glucocorticoid-Inducible Kinase (SGK)-1 in Senescence: A Novel Molecular Target Against Age-Related Diseases
Current Medicinal Chemistry Stem Cell Differentiation Stage Factors from Zebrafish Embryo: A Novel Strategy to Modulate the Fate of Normal and Pathological Human (Stem) Cells
Current Pharmaceutical Biotechnology Therapeutic Options for the Management of Aromatase Inhibitor- Associated Bone Loss
Endocrine, Metabolic & Immune Disorders - Drug Targets Antisense Oligonucleotides in the Treatment of Cerebral Gliomas. Review of Concerning Patents
Recent Patents on CNS Drug Discovery (Discontinued) HPV Cervical Infection and Immunodysregulation: Synergistic Risks for Neoplasia-Review
Current Women`s Health Reviews The Transcriptional Regulation of the Human CYP2C Genes
Current Drug Metabolism Protein Kinase C Isozymes as Potential Targets for Anticancer Therapy
Current Cancer Drug Targets Therapeutic Targeting of Cancers with Loss of PTEN Function
Current Drug Targets Defense-related Proteins from Chelidonium majus L. as Important Components of its Latex
Current Protein & Peptide Science Molecular Pathways in the Progression of Hormone-Independent and Metastatic Prostate Cancer
Current Cancer Drug Targets Reversing Breast Cancer Stem Cell into Breast Somatic Stem Cell
Current Pharmaceutical Biotechnology How Do Microtubule-Targeted Drugs Work? An Overview
Current Cancer Drug Targets Molecular Targeting of Drug Delivery Systems to Cancer
Current Drug Targets Curcumin and Curcumin-like Molecules: From Spice to Drugs
Current Medicinal Chemistry RNA Splicing Manipulation: Strategies to Modify Gene Expression for a Variety of Therapeutic Outcomes
Current Gene Therapy A Recent Update on the Role of Ghrelin in Glucose Homeostasis
Current Diabetes Reviews